Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing

1. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005;
438(7070):932–936.
2. Dvorak HF. Tumors: wounds that do not heal. Similarities between
tumor stroma generation and wound healing. N Engl J Med 1986;
315(26):1650–1659.
3. Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions.
Circ Res 2005;97(6):512–523.
4. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med
1971;285(21):1182–1186.
5. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or
with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;
355(24):2542–2550.
6. Jain RK, Duda DG, Clark JW, et al. Lessons from phase III clinical
trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;
3(1):24–40.
7. Folkman J, Watson K, Ingber D, et al. Induction of angiogenesis during
the transition from hyperplasia to neoplasia. Nature 1989;339(6219):
58–61.
8. Inoue M, Hager JH, Ferrara N, et al. VEGF-A has a critical, nonredundant
role in angiogenic switching and pancreatic beta cell carcinogenesis.
Cancer Cell 2002;1(2):193–202.
9. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-
9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol
2000;2(10):737–744.
10. Casanovas O, Hicklin DJ, Bergers G, et al. Drug resistance by evasion
of antiangiogenic targeting of VEGF signaling in late-stage pancreatic
islet tumors. Cancer Cell 2005;8(4):299–309.
11. Gimbrone MA Jr, Leapman SB, Cotran RS, et al. Tumor dormancy in vivo
by prevention of neovascularization. J Exp Med 1972;136(2):261–276.
12. Holmgren L, O’Reilly MS, Folkman J. Dormancy of micrometastases:
balanced proliferation and apoptosis in the presence of angiogenesis
suppression. Nat Med 1995;1(2):149–153.
13. Fox SB, Leek RD, Weekes MP, et al. Quantitation and prognostic
value of breast cancer angiogenesis: comparison of microvessel density,
Chalkley count, and computer image analysis. J Pathol 1995;177(3):
275–283.
14. Buadu LD, Murakami J, Murayama S, et al. Breast lesions: correlation of
contrast medium enhancement patterns on MR images with histopathologic
findings and tumor angiogenesis. Radiology 1996;200(3):639–649.
15. Tanaka F, Otake Y, Yanagihara K, et al. Evaluation of angiogenesis in
non-small cell lung cancer: comparison between anti-CD34 antibody
and anti-CD105 antibody. Clin Cancer Res 2001;7(11):3410–3415.
16. Baeten CI, Castermans K, Hillen HF, et al. Proliferating endothelial
cells and leukocyte infiltration as prognostic markers in colorectal cancer.
Clin Gastroenterol Hepatol 2006;4(11):1351–1357.
17. Schor AM, Pazouki S, Morris J, et al. Heterogeneity in microvascular
density in lung tumours: comparison with normal bronchus. Br J Cancer
1998;77(6):946–951.
18. Swinson DE, Jones JL, Richardson D, et al. Carbonic anhydrase IX
expression, a novel surrogate marker of tumor hypoxia, is associated
with a poor prognosis in non-small-cell lung cancer. J Clin Oncol 2003;
21(3):473–482.
19. Raleigh JA, Chou SC, Arteel GE, et al. Comparisons among pimonidazole
binding, oxygen electrode measurements, and radiation response
in C3H mouse tumors. Radiat Res 1999;151(5):580–589.
20. Varia MA, Calkins-Adams DP, Rinker LH, et al. Pimonidazole: a novel
hypoxia marker for complementary study of tumor hypoxia and cell proliferation
in cervical carcinoma. Gynecol Oncol 1998;71(2):270–277.
21. Mathias CJ, Welch MJ, Kilbourn MR, et al. Radiolabeled hypoxic
cell sensitizers: tracers for assessment of ischemia. Life Sci 1987;41(2):
199–206.
22. Hladovec J, Rossmann P. Circulating endothelial cells isolated together
with platelets and the experimental modification of their counts in rats.
Thromb Res 1973;3:665–674.
23. Hladovec J, Prerovsky I, Stanek V, et al. Circulating endothelial cells
in acute myocardial infarction and angina pectoris. Klin Wochenschr
1978;56(20):1033–1036.
24. Bertolini F, Shaked Y, Mancuso P, et al. The multifaceted circulating
endothelial cell in cancer: towards marker and target identification. Nat
Rev Cancer 2006;6(11):835–845.
25. McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope
to clinic. Nat Med 2003;9(6):713–725.
26. Guidi AJ, Fischer L, Harris JR, et al. Microvessel density and distribution
in ductal carcinoma in situ of the breast. J Natl Cancer Inst
1994;86(8):614–619.
27. Brown LF, Guidi AJ, Schnitt SJ, et al. Vascular stroma formation in
carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the
breast. Clin Cancer Res 1999;5(5):1041–1056.
28. Smith-McCune KK, Weidner N. Demonstration and characterization
of the angiogenic properties of cervical dysplasia. Cancer Res 1994;
54(3):800–804.
29. Merrick DT, Haney J, Petrunich S, et al. Overexpression of vascular endothelial
growth factor and its receptors in bronchial dypslasia demonstrated
by quantitative RT-PCR analysis. Lung Cancer 2005;48(1):31–45.
30. Keith RL, Miller YE, Gemmill RM, et al. Angiogenic squamous dysplasia
in bronchi of individuals at high risk for lung cancer. Clin Cancer
Res 2000;6(5):1616–1625.
31. Hockel M, Knoop C, Schlenger K, et al. Intratumoral pO2 predicts
survival in advanced cancer of the uterine cervix. Radiother Oncol 1993;
26(1):45–50.
32. Brizel DM, Scully SP, Harrelson JM, et al. Tumor oxygenation predicts
for the likelihood of distant metastases in human soft tissue sarcoma.
Cancer Res 1996;56(5):941–943.
33. Dameron KM, Volpert OV, Tainsky MA, et al. Control of angiogenesis
in fibroblasts by p53 regulation of thrombospondin-1. Science
1994;265(5178):1582–1584.
34. Phillips RJ, Mestas J, Gharaee-Kermani M, et al. Epidermal growth
factor and hypoxia-induced expression of CXC chemokine receptor 4
on non-small cell lung cancer cells is regulated by the phosphatidylinositol
3-kinase/PTEN/AKT/mammalian target of rapamycin signaling
pathway and activation of hypoxia inducible factor-1alpha. J Biol Chem
2005;280(23):22473–22481.
35. Phillips RJ, Burdick MD, Lutz M, et al. The stromal derived factor-
1/CXCL12-CXC chemokine receptor 4 biological axis in non-small
cell lung cancer metastases. Am J Respir Crit Care Med 2003;167(12):
1676–1686.
36. Shweiki D, Neeman M, Itin A, et al. Induction of vascular endothelial
growth factor expression by hypoxia and by glucose deficiency in multicell
spheroids: implications for tumor angiogenesis. Proc Natl Acad Sci
U S A 1995;92(3):768–772.
37. Gerhardt H, Golding M, Fruttiger M, et al. VEGF guides angiogenic
sprouting utilizing endothelial tip cell filopodia. J Cell Biol 2003;
161(6):1163–1177.
38. Dome B, Hendrix MJ, Paku S, et al. Alternative vascularization mechanisms
in cancer: pathology and therapeutic implications. Am J Pathol
2007;170(1):1–15.
39. Paku S, Paweletz N. First steps of tumor-related angiogenesis. Lab Invest
1991;65(3):334–346.
40. Lamalice L, Le Boeuf F, Huot J. Endothelial cell migration during angiogenesis.
Circ Res 2007;100(6):782–794.
41. Wels J, Kaplan RN, Rafii S, et al. Migratory neighbors and distant invaders:
tumor-associated niche cells. Genes Dev 2008;22(5):559–574.
42. Ausprunk DH, Folkman J. Migration and proliferation of endothelial
cells in preformed and newly formed blood vessels during tumor angiogenesis.
Microvasc Res 1977;14(1):53–65.
43. Lamagna C, Bergers G. The bone marrow constitutes a reservoir of
pericyte progenitors. J Leukoc Biol 2006;80(4):677–681.
44. Benjamin LE, Golijanin D, Itin A, et al. Selective ablation of immature
blood vessels in established human tumors follows vascular endothelial
growth factor withdrawal. J Clin Invest 1999;103(2):159–65.
45. Hasumi Y, Klosowska-Wardega A, Furuhashi M, et al. Identification
of a subset of pericytes that respond to combination therapy targeting
PDGF and VEGF signaling. Int J Cancer 2007;121(12):2606–2614.
46. De Palma M, Venneri MA, Galli R, et al. Tie2 identifies a hematopoietic
lineage of proangiogenic monocytes required for tumor vessel formation
and a mesenchymal population of pericyte progenitors. Cancer
Cell 2005;8(3):211–226.
47. Bababeygy SR, Cheshier SH, Hou LC, et al. Hematopoietic stem cellderived
pericytic cells in brain tumor angio-architecture. Stem Cells Dev
2008;17(1):11–18.
48. Yamashita J, Itoh H, Hirashima M, et al. Flk1-positive cells derived
from embryonic stem cells serve as vascular progenitors. Nature 2000;
408(6808):92–96.
49. Takahashi T, Kalka C, Masuda H, et al. Ischemia- and cytokineinduced
mobilization of bone marrow-derived endothelial progenitor
cells for neovascularization. Nat Med 1999;5(4):434–438.
50. Li B, Sharpe EE, Maupin AB, et al. VEGF and PlGF promote adult
vasculogenesis by enhancing EPC recruitment and vessel formation at
the site of tumor neovascularization. Faseb J 2006;20(9):1495–1497.
51. Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island
formation and vasculogenesis in Flk-1-deficient mice. Nature 1995;
376(6535):62–66.
52. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bonemarrow-
derived endothelial and hematopoietic precursor cells blocks
tumor angiogenesis and growth. Nat Med 2001;7(11):1194–1201.
53. De Falco E, Porcelli D, Torella AR, et al. SDF-1 involvement in endothelial
phenotype and ischemia-induced recruitment of bone marrow
progenitor cells. Blood 2004;104(12):3472–3482.
54. Kalka C, Tehrani H, Laudenberg B, et al. VEGF gene transfer mobilizes
endothelial progenitor cells in patients with inoperable coronary
disease. Ann Thorac Surg 2000;70(3):829–834.
55. Lyden D, Young AZ, Zagzag D, et al. Id1 and Id3 are required for
neurogenesis, angiogenesis and vascularization of tumour xenografts.
Nature 1999;401(6754):670–677.
56. Gao D, Nolan DJ, Mellick AS, et al. Endothelial progenitor cells control
the angiogenic switch in mouse lung metastasis. Science 2008;
319(5860):195–198.
57. Suriano R, Chaudhuri D, Johnson RS, et al. 17Beta-estradiol mobilizes
bone marrow-derived endothelial progenitor cells to tumors. Cancer
Res 2008;68(15):6038–6042.
58. Shaked Y, Ciarrocchi A, Franco M, et al. Therapy-induced acute recruitment
of circulating endothelial progenitor cells to tumors. Science
2006;313(5794):1785–1787.
59. Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive
human breast carcinomas promote tumor growth and angiogenesis
through elevated SDF-1/CXCL12 secretion. Cell 2005;121(3):335–348.
60. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the
VEGF-specific antibody bevacizumab has antivascular effects in human
rectal cancer. Nat Med 2004;10(2):145–147.
61. Purhonen S, Palm J, Rossi D, et al. Bone marrow-derived circulating
endothelial precursors do not contribute to vascular endothelium and
are not needed for tumor growth. Proc Natl Acad Sci U S A 2008;
105(18):6620–6625.
62. Kerbel RS, Benezra R, Lyden DC, et al. Endothelial progenitor cells are
cellular hubs essential for neoangiogenesis of certain aggressive adenocarcinomas
and metastatic transition but not adenomas. Proc Natl Acad
Sci U S A 2008;105(34):E54; author reply E55.
63. Peters BA, Diaz LA, Polyak K, et al. Contribution of bone marrowderived
endothelial cells to human tumor vasculature. Nat Med 2005;
11(3):261–262.
64. Nolan DJ, Ciarrocchi A, Mellick AS, et al. Bone marrow-derived endothelial
progenitor cells are a major determinant of nascent tumor
neovascularization. Genes Dev 2007;21(12):1546–1558.
65. Lin Y, Weisdorf DJ, Solovey A, et al. Origins of circulating endothelial
cells and endothelial outgrowth from blood. J Clin Invest 2000;
105(1):71–77.
66. Furstenberger G, von Moos R, Senn HJ, et al. Real-time PCR of
CD146 mRNA in peripheral blood enables the relative quantification
of circulating endothelial cells and is an indicator of angiogenesis. Br J
Cancer 2005;93(7):793–798.
67. Duda DG, Cohen KS, di Tomaso E, et al. Differential CD146 expression
on circulating versus tissue endothelial cells in rectal cancer
patients: implications for circulating endothelial and progenitor cells
as biomarkers for antiangiogenic therapy. J Clin Oncol 2006;24(9):
1449–1453.
68. Bagley RG, Rouleau C, St Martin T, et al. Human endothelial precursor
cells express tumor endothelial marker 1/endosialin/CD248. Mol
Cancer Ther 2008;7(8):2536–2546.
69. Nagano N, Sasaki H, Aoyagi M, et al. Invasion of experimental rat
brain tumor: early morphological changes following microinjection of
C6 glioma cells. Acta Neuropathol 1993;86(2):117–125.
70. Pages F, Berger A, Camus M, et al. Effector memory T cells, early
metastasis, and survival in colorectal cancer. N Engl J Med 2005;
353(25):2654–2666.
71. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune
system during cancer development. Nat Rev Cancer 2006;6(1):24–37.
72. Bellocq A, Antoine M, Flahault A, et al. Neutrophil alveolitis in bronchioloalveolar
carcinoma: induction by tumor-derived interleukin-8
and relation to clinical outcome. Am J Pathol 1998;152(1):83–92.
73. Al-Shibli KI, Donnem T, Al-Saad S, et al. Prognostic effect of epithelial
and stromal lymphocyte infiltration in non-small cell lung cancer. Clin
Cancer Res 2008;14(16):5220–5227.
74. Kawai O, Ishii G, Kubota K, et al. Predominant infiltration of macrophages
and CD8( ) T Cells in cancer nests is a significant predictor
of survival in stage IV nonsmall cell lung cancer. Cancer
2008;113(6):1387–1395.
75. Lewis C, Murdoch C. Macrophage responses to hypoxia: implications
for tumor progression and anti-cancer therapies. Am J Pathol
2005;167(3):627–635.
76. Pollard JW. Tumour-educated macrophages promote tumour progression
and metastasis. Nat Rev Cancer 2004;4(1):71–78.
77. Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization:
tumor-associated macrophages as a paradigm for polarized M2 mononuclear
phagocytes. Trends Immunol 2002;23(11):549–555.
78. Lin EY, Li JF, Gnatovskiy L, et al. Macrophages regulate the angiogenic
switch in a mouse model of breast cancer. Cancer Res 2006;
66(23):11238–11246.
79. Nakao S, Kuwano T, Tsutsumi-Miyahara C, et al. Infiltration of COX-
2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization
and tumor growth. J Clin Invest 2005;115(11):2979–2991
80. Giraudo E, Inoue M, Hanahan D. An amino-bisphosphonate targets
MMP-9-expressing macrophages and angiogenesis to impair cervical
carcinogenesis. J Clin Invest 2004;114(5):623–633.
81. Ahn GO, Brown JM. Matrix metalloproteinase-9 is required for tumor
vasculogenesis but not for angiogenesis: role of bone marrow-derived
myelomonocytic cells. Cancer Cell 2008;13(3):193–205.
82. Chen JJ, Yao PL, Yuan A, et al. Up-regulation of tumor interleukin-8
expression by infiltrating macrophages: its correlation with tumor
angiogenesis and patient survival in non-small cell lung cancer. Clin
Cancer Res 2003;9(2):729–737.
83. Salven P, Hattori K, Heissig B, et al. Interleukin-1alpha promotes angiogenesis
in vivo via VEGFR-2 pathway by inducing inflammatory
cell VEGF synthesis and secretion. Faseb J 2002;16(11):1471–1473.
84. Welsh TJ, Green RH, Richardson D, et al. Macrophage and mast-cell
invasion of tumor cell islets confers a marked survival advantage in
non-small-cell lung cancer. J Clin Oncol 2005;23(35):8959–8967.
85. Kawai O, Ishii G, Kubota K, et al. Predominant infiltration of macrophages
and CD8( ) T Cells in cancer nests is a significant predictor
of survival in stage IV nonsmall cell lung cancer. Cancer 2008;
113(6):1387–1395.
86. Yao L, Sgadari C, Furuke K, et al. Contribution of natural killer cells
to inhibition of angiogenesis by interleukin-12. Blood 1999;93(5):
1612–1621.
87. Hayakawa Y, Takeda K, Yagita H, et al. IFN-gamma-mediated inhibition
of tumor angiogenesis by natural killer T-cell ligand, alphagalactosylceramide.
Blood 2002;100(5):1728–1733.
88. Coussens LM, Raymond WW, Bergers G, et al. Inflammatory mast
cells up-regulate angiogenesis during squamous epithelial carcinogenesis.
Genes Dev 1999;13(11):1382–1397.
89. Ibaraki T, Muramatsu M, Takai S, et al. The relationship of tryptaseand
chymase-positive mast cells to angiogenesis in stage I non-small
cell lung cancer. Eur J Cardiothorac Surg 2005;28(4):617–621.
90. Fukumura D, Xavier R, Sugiura T, et al. Tumor induction of VEGF
promoter activity in stromal cells. Cell 1998;94(6):715–725.
91. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006;
6(5):392–401.
92. Matsumoto K, Nakamura T. Hepatocyte growth factor and the Met
system as a mediator of tumor-stromal interactions. Int J Cancer
2006;119(3):477–483.
93. Jodele S, Chantrain CF, Blavier L, et al. The contribution of bone
marrow-derived cells to the tumor vasculature in neuroblastoma is matrix
metalloproteinase-9 dependent. Cancer Res 2005;65(8):3200–3208.
94. Kalluri R. Basement membranes: structure, assembly and role in tumour
angiogenesis. Nat Rev Cancer 2003;3(6):422–433.
95. Leighl NB, Paz-Ares L, Douillard JY, et al. Randomized phase III study
of matrix metalloproteinase inhibitor BMS-275291 in combination
with paclitaxel and carboplatin in advanced non-small-cell lung cancer:
National Cancer Institute of Canada-Clinical Trials Group Study
BR.18. J Clin Oncol 2005;23(12):2831–2839.
96. Ribatti D, Vacca A, Roncali L, et al. The chick embryo chorioallantoic
membrane as a model for in vivo research on angiogenesis. Int J Dev
Biol 1996;40(6):1189–1197.
97. Folkman J. Angiogenesis: an organizing principle for drug discovery?
Nat Rev Drug Discov 2007;6(4):273–286.
98. Dvorak HF, Orenstein NS, Carvalho AC, et al. Induction of a fibringel
investment: an early event in line 10 hepatocarcinoma growth mediated
by tumor-secreted products. J Immunol 1979;122(1):166–174.
99. Connolly DT, Heuvelman DM, Nelson R, et al. Tumor vascular permeability
factor stimulates endothelial cell growth and angiogenesis.
J Clin Invest 1989;84(5):1470–1478.
100. Quinn TP, Peters KG, De Vries C, et al. Fetal liver kinase 1 is a receptor
for vascular endothelial growth factor and is selectively expressed in vascular
endothelium. Proc Natl Acad Sci U S A 1993;90(16):7533–7537.
101. Barleon B, Sozzani S, Zhou D, et al. Migration of human monocytes
in response to vascular endothelial growth factor (VEGF) is mediated
via the VEGF receptor flt-1. Blood 1996;87(8):3336–3343.
102. Hattori K, Heissig B, Wu Y, et al. Placental growth factor reconstitutes
hematopoiesis by recruiting VEGFR1( ) stem cells from bone-marrow
microenvironment. Nat Med 2002;8(8):841–849.
103. Decaussin M, Sartelet H, Robert C, et al. Expression of vascular endothelial
growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and
VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation
with angiogenesis and survival. J Pathol 1999;188(4):369–377.
104. Fong GH, Zhang L, Bryce DM, et al. Increased hemangioblast commitment,
not vascular disorganization, is the primary defect in flt-1
knock-out mice. Development 1999;126(13):3015–3025.
105. Hiratsuka S, Minowa O, Kuno J, et al. Flt-1 lacking the tyrosine kinase
domain is sufficient for normal development and angiogenesis in mice.
Proc Natl Acad Sci U S A 1998;95(16):9349–9354.
106. Rahimi N. VEGFR-1 and VEGFR-2: two non-identical twins with a
unique physiognomy. Front Biosci 2006;11:818–829.
107. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis in
health and disease. Cancer Cell 2002;1(3):219–227.
108. Laakkonen P, Waltari M, Holopainen T, et al. Vascular endothelial
growth factor receptor 3 is involved in tumor angiogenesis and growth.
Cancer Res 2007;67(2):593–599.
109. Ji H, Ramsey MR, Hayes DN, et al. LKB1 modulates lung cancer differentiation
and metastasis. Nature 2007;448(7155):807–810.
110. Maity A, Pore N, Lee J, et al. Epidermal growth factor receptor transcriptionally
up-regulates vascular endothelial growth factor expression
in human glioblastoma cells via a pathway involving phosphatidylinositol
3 -kinase and distinct from that induced by hypoxia. Cancer Res
2000;60(20):5879–5886.
111. Arbiser JL, Moses MA, Fernandez CA, et al. Oncogenic H-ras stimulates
tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci
U S A 1997;94(3):861–866.
112. Xu H, Czerwinski P, Hortmann M, et al. Protein kinase C alpha promotes
angiogenic activity of human endothelial cells via induction of
vascular endothelial growth factor. Cardiovasc Res 2008;78(2):349–355.
113. Pore N, Jiang Z, Gupta A, et al. EGFR tyrosine kinase inhibitors
decrease VEGF expression by both hypoxia-inducible factor (HIF)-
1- independent and HIF-1-dependent mechanisms. Cancer Res 2006;
66(6):3197–3204.
114. Mukhopadhyay D, Tsiokas L, Zhou XM, et al. Hypoxic induction of
human vascular endothelial growth factor expression through c-Src activation.
Nature 1995;375(6532):577–581.
115. Mukhopadhyay D, Tsiokas L, Sukhatme VP. Wild-type p53 and v-Src
exert opposing influences on human vascular endothelial growth factor
gene expression. Cancer Res 1995;55(24):6161–6165.
116. Kieser A, Weich HA, Brandner G, et al. Mutant p53 potentiates protein
kinase C induction of vascular endothelial growth factor expression.
Oncogene 1994;9(3):963–969.
117. Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis
by p53-induced degradation of hypoxia-inducible factor
1alpha. Genes Dev 2000;14(1):34–44.
118. Matsumoto T, Bohman S, Dixelius J, et al. VEGF receptor-2 Y951 signaling
and a role for the adapter molecule TSAd in tumor angiogenesis.
Embo J 2005;24(13):2342–2353.
119. Gerber HP, McMurtrey A, Kowalski J, et al. Vascular endothelial
growth factor regulates endothelial cell survival through the phosphatidylinositol
3 -kinase/Akt signal transduction pathway. Requirement
for Flk-1/KDR activation. J Biol Chem 1998;273(46):30336–30343.
120. Wu LW, Mayo LD, Dunbar JD, et al. Utilization of distinct signaling
pathways by receptors for vascular endothelial cell growth factor and
other mitogens in the induction of endothelial cell proliferation. J Biol
Chem 2000;275(7):5096–5103.
121. Lampugnani MG, Orsenigo F, Gagliani MC, et al. Vascular endothelial
cadherin controls VEGFR-2 internalization and signaling from intracellular
compartments. J Cell Biol 2006;174(4):593–604.
122. Singh AJ, Meyer RD, Band H, et al. The carboxyl terminus of VEGFR-
2 is required for PKC-mediated down-regulation. Mol Biol Cell 2005;
16(4):2106–2118.
123. Soker S, Takashima S, Miao HQ, et al. Neuropilin-1 is expressed by
endothelial and tumor cells as an isoform-specific receptor for vascular
endothelial growth factor. Cell 1998;92(6):735–745.
124. Fuh G, Garcia KC, de Vos AM. The interaction of neuropilin-1 with
vascular endothelial growth factor and its receptor flt-1. J Biol Chem
2000;275(35):26690–26695.
125. Hong TM, Chen YL, Wu YY, et al. Targeting neuropilin 1 as an antitumor
strategy in lung cancer. Clin Cancer Res 2007;13(16):4759–4768.
126. Lamalice L, Houle F, Jourdan G, et al. Phosphorylation of tyrosine
1214 on VEGFR2 is required for VEGF-induced activation of Cdc42
upstream of SAPK2/p38. Oncogene 2004;23(2):434–445.
127. Lamalice L, Houle F, Huot J. Phosphorylation of Tyr1214 within
VEGFR-2 triggers the recruitment of Nck and activation of Fyn leading
to SAPK2/p38 activation and endothelial cell migration in response
to VEGF. J Biol Chem 2006;281(45):34009–34020.
128. Hiratsuka S, Nakamura K, Iwai S, et al. MMP9 induction by vascular
endothelial growth factor receptor-1 is involved in lung-specific metastasis.
Cancer Cell 2002;2(4):289–300.
129. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic
bone marrow progenitors initiate the pre-metastatic niche.
Nature 2005;438(7069):820–827.
130. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth
factor (VEGF) and their receptors. J Cell Sci 2001;114(Pt 5):853–865.
131. Poltorak Z, Cohen T, Sivan R, et al. VEGF145, a secreted vascular
endothelial growth factor isoform that binds to extracellular matrix.
J Biol Chem 1997;272(11):7151–7158.
132. Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor
(VEGF) isoforms: differential deposition into the subepithelial extracellular
matrix and bioactivity of extracellular matrix-bound VEGF.
Mol Biol Cell 1993;4(12):1317–1326.
133. Yuan A, Yu CJ, Kuo SH, et al. Vascular endothelial growth factor 189
mRNA isoform expression specifically correlates with tumor angiogenesis,
patient survival, and postoperative relapse in non-small-cell lung
cancer. J Clin Oncol 2001;19(2):432–441.
134. Lee YH, Tokunaga T, Oshika Y, et al. Cell-retained isoforms of vascular
endothelial growth factor (VEGF) are correlated with poor prognosis
in osteosarcoma. Eur J Cancer 1999;35(7):1089–1093.
135. Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGFdependent
modulation of capillary structure and endothelial cell survival
in vivo. Proc Natl Acad Sci U S A 2002;99(17):11205–11210.
136. Murdoch C, Tazzyman S, Webster S, et al. Expression of Tie-2 by
human monocytes and their responses to angiopoietin-2. J Immunol
2007;178(11):7405–7411.
137. Tanaka F, Ishikawa S, Yanagihara K, et al. Expression of angiopoietins
and its clinical significance in non-small cell lung cancer. Cancer Res
2002;62(23):7124–7129.
138. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression,
and growth in tumors mediated by angiopoietins and VEGF.
Science 1999;284(5422):1994–1998.
139. Metheny-Barlow LJ, Li LY. The enigmatic role of angiopoietin-1 in
tumor angiogenesis. Cell Res 2003;13(5):309–317.
140. Pennacchietti S, Michieli P, Galluzzo M, et al. Hypoxia promotes invasive
growth by transcriptional activation of the met protooncogene.
Cancer Cell 2003;3(4):347–361.
141. Rofstad EK, Rasmussen H, Galappathi K, et al. Hypoxia promotes
lymph node metastasis in human melanoma xenografts by up-regulating
the urokinase-type plasminogen activator receptor. Cancer Res
2002;62(6):1847–1853.
142. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection
of cells with diminished apoptotic potential in solid tumours [see comments].
Nature 1996;379(6560):88–91.
143. Teodoro JG, Parker AE, Zhu X, et al. p53-mediated inhibition of
angiogenesis through up-regulation of a collagen prolyl hydroxylase.
Science 2006;313(5789):968–971.
144. Steeg PS. Angiogenesis inhibitors: motivators of metastasis? Nat Med
2003;9(7):822–823.
145. Semenza GL. Hydroxylation of HIF-1: oxygen sensing at the molecular
level. Physiology (Bethesda) 2004;19:176–182.
146. Zelzer E, Levy Y, Kahana C, et al. Insulin induces transcription of target
genes through the hypoxia-inducible factor HIF-1alpha/ARNT.
Embo J 1998;17(17):5085–5094.
147. Yu AY, Frid MG, Shimoda LA, et al. Temporal, spatial, and oxygenregulated
expression of hypoxia-inducible factor-1 in the lung. Am J
Physiol 1998;275(4 Pt 1):L818–826.
148. Epstein AC, Gleadle JM, McNeill LA, et al. C. elegans EGL-9 and
mammalian homologs define a family of dioxygenases that regulate
HIF by prolyl hydroxylation. Cell 2001;107(1):43–54.
149. Yasuda H. Solid tumor physiology and hypoxia-induced chemo/radioresistance:
novel strategy for cancer therapy: nitric oxide donor as a
therapeutic enhancer. Nitric Oxide 2008;19(2):205–216
150. Hu CJ, Wang LY, Chodosh LA, et al. Differential roles of hypoxiainducible
factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene
regulation. Mol Cell Biol 2003;23(24):9361–9374.
151. Tian H, Hammer RE, Matsumoto AM, et al. The hypoxia-responsive
transcription factor EPAS1 is essential for catecholamine homeostasis
and protection against heart failure during embryonic development.
Genes Dev 1998;12(21):3320–3324.
152. Patel SA, Simon MC. Biology of hypoxia-inducible factor-2alpha in
development and disease. Cell Death Differ 2008;15(4):628–634.
153. Carroll VA, Ashcroft M. Role of hypoxia-inducible factor (HIF)-
1alpha versus HIF-2alpha in the regulation of HIF target genes in
response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-
Lindau function: implications for targeting the HIF pathway. Cancer
Res 2006;66(12):6264–6270.
154. Ryan HE, Lo J, Johnson RS. HIF-1 alpha is required for solid tumor
formation and embryonic vascularization. Embo J 1998;17(11):
3005–3015.
155. Leek RD, Talks KL, Pezzella F, et al. Relation of hypoxia-inducible
factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages
to tumor angiogenesis and the oxidative thymidine phosphorylase
pathway in Human breast cancer. Cancer Res 2002;62(5):
1326–1329.
156. Makino Y, Cao R, Svensson K, et al. Inhibitory PAS domain protein
is a negative regulator of hypoxia-inducible gene expression. Nature
2001;414(6863):550–554.
157. O’Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis
inhibitor that mediates the suppression of metastases by a Lewis
lung carcinoma. Cell 1994;79(2):315–328.
158. Dong Z, Kumar R, Yang X, et al. Macrophage-derived metalloelastase
is responsible for the generation of angiostatin in Lewis lung carcinoma.
Cell 1997;88(6):801–810.
159. Gately S, Twardowski P, Stack MS, et al. The mechanism of cancermediated
conversion of plasminogen to the angiogenesis inhibitor angiostatin.
Proc Natl Acad Sci U S A 1997;94(20):10868–10872.
160. Sharma MR, Rothman V, Tuszynski GP, et al. Antibody-directed targeting
of angiostatin’s receptor annexin II inhibits Lewis Lung Carcinoma
tumor growth via blocking of plasminogen activation: possible biochemical
mechanism of angiostatin’s action. Exp Mol Pathol 2006;81(2):
136–145.
161. O’Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor
of angiogenesis and tumor growth. Cell 1997;88(2):277–285.
162. Good DJ, Polverini PJ, Rastinejad F, et al. A tumor suppressor-dependent
inhibitor of angiogenesis is immunologically and functionally indistinguishable
from a fragment of thrombospondin. Proc Natl Acad Sci
U S A 1990;87(17):6624–6628.
163. Digtyar AV, Pozdnyakova NV, Feldman NB, et al. Endostatin: current
concepts about its biological role and mechanisms of action.
Biochemistry (Mosc) 2007;72(3):235–246.
164. Hamano Y, Kalluri R. Tumstatin, the NC1 domain of alpha3 chain
of type IV collagen, is an endogenous inhibitor of pathological angiogenesis
and suppresses tumor growth. Biochem Biophys Res Commun
2005;333(2):292–298.
206. Yasuda H, Yamaya M, Nakayama K, et al. Randomized phase II trial
comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine
and cisplatin alone in previously untreated stage IIIB/IV non-small-cell
lung cancer. J Clin Oncol 2006;24(4):688–694.
207. Macchiarini P, Fontanini G, Dulmet E, et al. Angiogenesis: an indicator
of metastasis in non-small cell lung cancer invading the thoracic
inlet. Ann Thorac Surg 1994;57(6):1534–1539.
208. Giatromanolaki A, Koukourakis M, O’Byrne K, et al. Prognostic
value of angiogenesis in operable non-small cell lung cancer. J Pathol
1996;179(1):80–88.
209. Fontanini G, Lucchi M, Vignati S, et al. Angiogenesis as a prognostic
indicator of survival in non-small-cell lung carcinoma: a prospective
study. J Natl Cancer Inst 1997;89(12):881–886.
210. Duarte IG, Bufkin BL, Pennington MF, et al. Angiogenesis as a predictor
of survival after surgical resection for stage I non-small-cell lung cancer.
J Thorac Cardiovasc Surg 1998;115(3):652–658; discussion 658–659.
211. D’Amico TA, Massey M, Herndon JE 2nd, et al. A biologic risk model
for stage I lung cancer: immunohistochemical analysis of 408 patients
with the use of ten molecular markers. J Thorac Cardiovasc Surg
1999;117(4):736–743.
212. Yano T, Tanikawa S, Fujie T, et al. Vascular endothelial growth factor
expression and neovascularisation in non-small cell lung cancer. Eur J
Cancer 2000;36(5):601–609.
213. Cox G, Walker RA, Andi A, et al. Prognostic significance of platelet
and microvessel counts in operable non-small cell lung cancer. Lung
Cancer 2000;29(3):169–177.
214. O’Byrne KJ, Koukourakis MI, Giatromanolaki A, et al. Vascular endothelial
growth factor, platelet-derived endothelial cell growth factor and angiogenesis
in non-small-cell lung cancer. Br J Cancer 2000;82(8):1427–1432.
215. Herbst RS, Onn A, Sandler A. Angiogenesis and lung cancer: prognostic
and therapeutic implications. J Clin Oncol 2005;23(14):3243–3256.
216. Donnem T, Al-Saad S, Al-Shibli K, et al. Inverse prognostic impact of
angiogenic marker expression in tumor cells versus stromal cells in non
small cell lung cancer. Clin Cancer Res 2007;13(22 Pt 1):6649–6657.
217. Chandrachud LM, Pendleton N, Chisholm DM, et al. Relationship
between vascularity, age and survival in non-small-cell lung cancer. Br J
Cancer 1997;76(10):1367–1375.
218. Fontanini G, Vignati S, Boldrini L, et al. Vascular endothelial growth
factor is associated with neovascularization and influences progression
of non-small cell lung carcinoma. Clin Cancer Res 1997;3(6):861–865.
219. Volm M, Koomagi R, Mattern J. Prognostic value of vascular endothelial
growth factor and its receptor Flt-1 in squamous cell lung cancer.
Int J Cancer 1997;74(1):64–68.
220. Han H, Silverman JF, Santucci TS, et al. Vascular endothelial growth
factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis
and a poor prognosis. Ann Surg Oncol 2001;8(1):72–79.
221. Giatromanolaki A, Koukourakis MI, Kakolyris S, et al. Vascular endothelial
growth factor, wild-type p53, and angiogenesis in early operable
non-small cell lung cancer. Clin Cancer Res 1998;4(12):3017–3024.
222. Fontanini G, Faviana P, Lucchi M, et al. A high vascular count and
overexpression of vascular endothelial growth factor are associated with
unfavourable prognosis in operated small cell lung carcinoma. Br J
Cancer 2002;86(4):558–563.
223. Salven P, Ruotsalainen T, Mattson K, et al. High pre-treatment serum
level of vascular endothelial growth factor (VEGF) is associated with poor
outcome in small-cell lung cancer. Int J Cancer 1998;79(2):144–146.
224. Iwasaki A, Kuwahara M, Yoshinaga Y, et al. Basic fibroblast growth
factor (bFGF) and vascular endothelial growth factor (VEGF) levels,
as prognostic indicators in NSCLC. Eur J Cardiothorac Surg 2004;
25(3):443–448.
225. Yuan A, Yu CJ, Shun CT, et al. Total cyclooxygenase-2 mRNA levels
correlate with vascular endothelial growth factor mRNA levels, tumor
angiogenesis and prognosis in non-small cell lung cancer patients. Int J
Cancer 2005;115(4):545–555.
226. Dome B, Timar J, Dobos J, et al. Identification and clinical significance
of circulating endothelial progenitor cells in human non-small cell lung
cancer. Cancer Res 2006;66(14):7341–7347.
227. Kaya A, Ciledag A, Gulbay BE, et al. The prognostic significance of
vascular endothelial growth factor levels in sera of non-small cell lung
cancer patients. Respir Med 2004;98(7):632–636.
228. Laack E, Scheffler A, Burkholder I, et al. Pretreatment vascular endothelial
growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9)
serum levels in patients with metastatic non-small cell lung cancer
(NSCLC). Lung Cancer 2005;50(1):51–58.
229. Bremnes RM, Camps C, Sirera R. Angiogenesis in non-small cell lung
cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF
and bFGF in tumours and blood. Lung Cancer 2006;51(2):143–158.
230. Mack PC, Redman MW, Chansky K, et al. Lower osteopontin plasma
levels are associated with superior outcomes in advanced non-small-cell
lung cancer patients receiving platinum-based chemotherapy: SWOG
Study S0003. J Clin Oncol 2008;26(29):4771–4776.
231. Heist RS, Zhai R, Liu G, et al. VEGF polymorphisms and survival in
early-stage non-small-cell lung cancer. J Clin Oncol 2008;26(6):856–862.
232. Smith DR, Polverini PJ, Kunkel SL, et al. Inhibition of interleukin
8 attenuates angiogenesis in bronchogenic carcinoma. J Exp Med
1994;179(5):1409–1415.
233. Zhang L, Chen J, Ke Y, et al. Expression of Placenta growth factor
(PlGF) in non-small cell lung cancer (NSCLC) and the clinical and
prognostic significance. World J Surg Oncol 2005;3:68.
234. Chen J, Ye L, Zhang L, et al. Placenta growth factor, PLGF, influences
the motility of lung cancer cells, the role of Rho associated kinase,
Rock1. J Cell Biochem 2008;105(1):313–320.
235. Yuan A, Yu CJ, Luh KT, et al. Aberrant p53 expression correlates with
expression of vascular endothelial growth factor mRNA and interleukin-
8 mRNA and neoangiogenesis in non-small-cell lung cancer. J Clin
Oncol 2002;20(4):900–910.
236. Tsao MS, Aviel-Ronen S, Ding K, et al. Prognostic and predictive importance
of p53 and RAS for adjuvant chemotherapy in non small-cell
lung cancer. J Clin Oncol 2007;25(33):5240–5247.
237. Giatromanolaki A, Koukourakis MI, Sowter HM, et al. BNIP3 expression
is linked with hypoxia-regulated protein expression and with
poor prognosis in non-small cell lung cancer. Clin Cancer Res 2004;
10(16):5566–5571.
238. Swinson DE, Jones JL, Cox G, et al. Hypoxia-inducible factor-1 alpha
in non small cell lung cancer: relation to growth factor, protease and
apoptosis pathways. Int J Cancer 2004;111(1):43–50.
239. Felip E, Taron M, Rosell R, et al. Clinical significance of hypoxiainducible
factor-1a messenger RNA expression in locally advanced
non-small-cell lung cancer after platinum agent and gemcitabine chemotherapy
followed by surgery. Clin Lung Cancer 2005;6(5):299–303.
240. Eschmann SM, Paulsen F, Reimold M, et al. Prognostic impact of
hypoxia imaging with 18F-misonidazole PET in non-small cell lung
cancer and head and neck cancer before radiotherapy. J Nucl Med
2005;46(2):253–260.
241. Dehdashti F, Mintun MA, Lewis JS, et al. In vivo assessment of tumor
hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging
2003;30(6):844–850.
242. Welsh SJ, Bellamy WT, Briehl MM, et al. The redox protein thioredoxin-
1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression:
Trx-1 overexpression results in increased vascular endothelial
growth factor production and enhanced tumor angiogenesis. Cancer
Res 2002;62(17):5089–5095.
243. Kakolyris S, Giatromanolaki A, Koukourakis M, et al. Thioredoxin expression
is associated with lymph node status and prognosis in early operable
non-small cell lung cancer. Clin Cancer Res 2001;7(10):3087–3091.
244. Siegfried JM, Weissfeld LA, Luketich JD, et al. The clinical significance
of hepatocyte growth factor for non-small cell lung cancer. Ann Thorac
Surg 1998;66(6):1915–1918.
245. Kong-Beltran M, Seshagiri S, Zha J,et al. Somatic mutations lead to an oncogenic
deletion of met in lung cancer. Cancer Res 2006;66(1):283–289.
246. Pircher A, Kähler CM, Skvortsov S, et al. Increased numbers of endothelial
progenitor cells in peripheral blood and tumor specimens in
non-small cell lung cancer: a methodological challenge and an ongoing
debate on the clinical relevance. Oncol Rep 2008;19(2):345–352.
247. Li A, Dubey S, Varney ML, et al. IL-8 directly enhanced endothelial
cell survival, proliferation, and matrix metalloproteinases production
and regulated angiogenesis. J Immunol 2003;170(6):3369–3376.
248. Zhu YM, Webster SJ, Flower D, et al. Interleukin-8/CXCL8 is a growth
factor for human lung cancer cells. Br J Cancer 2004;91(11):1970–1976.
249. Pastorino U, Andreola S, Tagliabue E, et al. Immunocytochemical markers
in stage I lung cancer: relevance to prognosis. J Clin Oncol 1997;
15(8):2858–2865.
250. Pezzella F, Pastorino U, Tagliabue E, et al. Non-small-cell lung carcinoma
tumor growth without morphological evidence of neo-angiogenesis.
Am J Pathol 1997;151(5):1417–1423.
251. Renyi-Vamos F, Tovari J, Fillinger J, et al. Lymphangiogenesis correlates
with lymph node metastasis, prognosis, and angiogenic phenotype
in human non-small cell lung cancer. Clin Cancer Res 2005;11(20):
7344–7353.
252. Mattern J, Koomägi R, Volm M. Biological characterization of subgroups
of squamous cell lung carcinomas. Clin Cancer Res 1999;5(6):1459–1463.
253. Giatromanolaki A, Koukourakis MI, O’Byrne K, et al. Non-small cell
lung cancer: c-erbB-2 overexpression correlates with low angiogenesis
and poor prognosis. Anticancer Res 1996;16(6B):3819–3825.
254. He Y, Kozaki K, Karpanen T, et al. Suppression of tumor lymphangiogenesis
and lymph node metastasis by blocking vascular endothelial growth
factor receptor 3 signaling. J Natl Cancer Inst 2002;94(11):819–825.
255. Tamura M, Oda M, Tsunezuka Y, et al. Chest CT and serum vascular
endothelial growth factor-C level to diagnose lymph node metastasis
in patients with primary non-small cell lung cancer. Chest 2004;
126(2):342–346.
256. Fisher GH, Wellen SL, Klimstra D, et al. Induction and apoptotic regression
of lung adenocarcinomas by regulation of a K-Ras transgene in
the presence and absence of tumor suppressor genes. Genes Dev 2001;
15(24):3249–3262.
257. Konishi T, Huang CL, Adachi M, et al. The K-ras gene regulates vascular
endothelial growth factor gene expression in non-small cell lung
cancers. Int J Oncol 2000;16(3):501–511.
258. Tsao MS, Liu N, Nicklee T, et al. Angiogenesis correlates with vascular
endothelial growth factor expression but not with Ki-ras oncogene
activation in non-small cell lung carcinoma. Clin Cancer Res 1997;
3(10):1807–1814.
259. Johnson L, Mercer K, Greenbaum D, et al. Somatic activation of the
K-ras oncogene causes early onset lung cancer in mice. Nature 2001;
410(6832):1111–1116.
260. Jackson EL, Willis N, Mercer K, et al. Analysis of lung tumor initiation
and progression using conditional expression of oncogenic K-ras. Genes
Dev 2001;15(24):3243–3248.
261. Kissil JL, Walmsley MJ, Hanlon L, et al. Requirement for Rac1 in a K-ras
induced lung cancer in the mouse. Cancer Res 2007;67(17):8089–8094.
262. Iwanaga K, Yang Y, Raso MG, et al. Pten inactivation accelerates oncogenic
K-ras-initiated tumorigenesis in a mouse model of lung cancer.
Cancer Res 2008;68(4):1119–1127.
263. Yang Y, Wislez M, Fujimoto N, et al. A selective small molecule inhibitor
of c-Met, PHA-665752, reverses lung premalignancy induced by
mutant K-ras. Mol Cancer Ther 2008;7(4):952–960.
264. Puri N, Khramtsov A, Ahmed S, et al. A selective small molecule inhibitor
of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis
in mouse lung cancer xenografts. Cancer Res 2007;67(8):3529–3534.
265. Wislez M, Fujimoto N, Izzo JG, et al. High expression of ligands for
chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by
oncogenic kras. Cancer Res 2006;66(8):4198–4207.
266. Kerkhoff E, Fedorov LM, Siefken R, et al. Lung-targeted expression
of the c-Raf-1 kinase in transgenic mice exposes a novel oncogenic
character of the wild-type protein. Cell Growth Differ 2000;11(4):
185–190.
267. Ceteci F, Ceteci S, Karreman C, et al. Disruption of tumor cell adhesion
promotes angiogenic switch and progression to micrometastasis in
RAF-driven murine lung cancer. Cancer Cell 2007;12(2):145–159.
268. Kulke MH, Bergsland EK, Ryan DP, et al. Phase II study of recombinant
human endostatin in patients with advanced neuroendocrine
tumors. J Clin Oncol 2006;24(22):3555–3561.